| Description | Evatanepag (CP-533536 free acid) is an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation with EC50 of 0.3 nM.CP-533536 demonstrated the ability to heal fractures when administered locally as a single dose in rat models of fracture healing. |
| In vitro | CP-533536 is a potent and selective EP2agonist. CP-533536 shows the ability to heal fractures when administered locally as a single dose in rat models of fracture healing s excellent in vitro potency and it also displays against EP2 and selectivity against a broad panel of other targets. |
| Synonyms | CP-533536 free acid, 2-[3-[N-(4-叔丁基苄基)-N-(吡啶-3-基磺酰基)氨基甲基]苯氧基]乙酸 |
| molecular weight | 468.57 |
| Molecular formula | C25H28N2O5S |
| CAS | 223488-57-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 32 mg/mL (68.29 mM) |
| References | 1. Cameron KO, et al. Discovery of CP-533536: an EP2 receptor selective prostaglandin E2 (PGE2) agonist that induces local bone formation. Bioorg Med Chem Lett. 2009 Apr 1;19(7):2075-8. |